Duchenne muscular dystrophy (DMD) is a genetic muscular disorder characterised by progressive muscular weakness and wasting, with cardiac complications (such as dilated cardiomyopathy) and respiratory muscle failure arising in the late stage. To investigate mechanisms of dilated cardiomyopathy in DMD, Lei Yang and collaborators derived cardiomyocytes (CMs) from DMD-patient-specific induced pluripotent stem cells (iPSCs). Compared to control cells, DMD iPSC-CMs exhibited elevated cytosolic calcium, mitochondrial damage and increased cell apoptosis. To further dissect the mechanisms underlying these alterations, the authors performed transcriptional and translational analyses and identified a mitochondrially initiated molecular cascade – which involves CASPASE3 (CASP3) activation – as being responsible for the increased apoptosis in DMD iPSC-CMs. Notably, the application of the membrane sealant Poloxamer 188 could prevent calcium overload and CASP3 activation, significantly reducing apoptosis in these cells. Thus, the authors established a useful in vitro system to disclose mechanisms of cardiomyopathy in DMD and to identify molecular targets that could be pharmacologically manipulated. Page 457
Modelling DMD-associated cardiomyopathy in patient-derived iPSCs
Modelling DMD-associated cardiomyopathy in patient-derived iPSCs. Dis Model Mech 1 May 2015; 8 (5): e0503. doi:
Download citation file:
Advertisement
Cited by
Interviews with Biologists @ 100 conference speakers

Explore our interviews with keynote speakers from the Biologists @ 100 conference, hosted to celebrate our publisher’s 100th anniversary, where we discuss climate change and biodiversity with Hans-Otto Pörtner and Jane Francis, health and disease with Charles Swanton and Sadaf Farooqi, and emerging technologies with Manu Prakash and Jennifer Lippincott-Schwartz.
A new perspective on disease research
DMM publishes perspectives – peer-reviewed articles that provide expert analysis of a topic important to the disease research community. Read our collection from authors presenting new or potentially controversial ideas or hypotheses, to help address future challenges and forge new directions.
Read & Publish Open Access publishing: what authors say

We have had great feedback from authors who have benefitted from our Read & Publish agreement with their institution and have been able to publish Open Access with us without paying an APC. Read what they had to say.
Fast & Fair peer review

Our sister journal Biology Open has recently launched the next phase of their Fast & Fair peer review initiative: offering high-quality peer review within 7 working days. To learn more about BiO’s progress and future plans, read the Editorial by Daniel Gorelick, or visit the Fast & Fair peer review page.
History of our journals

As our publisher, The Company of Biologists, turns 100 years old, read about DMM’s history and explore the journey of each of our sister journals: Development, Journal of Cell Science, Journal of Experimental Biology and Biology Open.
Other journals from
The Company of Biologists